Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.  [electronic resource] 

 -  The New England journal of medicine  Oct 2008 
 - 1786-801 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa0802670  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--adverse effects<br/>Adolescent<br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--adverse effects<br/>Autoimmune Diseases--chemically induced<br/>Female<br/>Humans<br/>Infections--chemically induced<br/>Interferon beta-1a<br/>Interferon-beta--adverse effects<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Purpura, Thrombocytopenic--chemically induced<br/>Thyroid Diseases--chemically induced<br/>Treatment Outcome